| ²é¿´: 172 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
wangshixiaowsx½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
ººÒëÓ¢
|
||
|
¿ª»·ºËÜÕÀ࿹²¡¶¾Ò©ÎïµÄÑо¿¸Å¿ö ÕªÒª£º¿ª»·ºËÜÕÀ࿹²¡¶¾Ò©Îï¾ßÓеͶ¾¡¢µÍÄÍÊÜÐԺ͹ãÆ×¿¹DNA²¡¶¾»îÐÔ£¬Æäǰҩ¸üÊÇÌá¸ßÁËÒ©ÎïµÄ¿Ú·þÉúÎïÀûÓöȡ£±¾ÎÄ×ÛÊöÁ˼¸ÖÖ³£¼û¿ª»·ºËÜÕÀàÒ©Îï¼°Æäǰҩ½üÄêµÄÑо¿½øÕ¹£¬ÔÚ´Ë»ù´¡ÉÏÕ¹ÍûÁË¿¹²¡¶¾Ò©ÎïµÄÑо¿·½Ïò¡£ [ Last edited by wangshixiaowsx on 2010-1-24 at 20:06 ] |
» ²ÂÄãϲ»¶
²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
081700ѧ˶£¬323·Ö£¬Ò»Ö¾Ô¸Öйúº£Ñó´óѧÇóµ÷¼ÁѧУ
ÒѾÓÐ15È˻ظ´
295Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸9²ÄÁÏѧ˶297ÒѹýÁù¼¶Çóµ÷¼ÁÍÆ¼ö
ÒѾÓÐ10È˻ظ´
312Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ12È˻ظ´
Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶
ÒѾÓÐ8È˻ظ´
¹¤¿Æ277·ÖÇóµ÷¼Á²ÄÁÏ
ÒѾÓÐ5È˻ظ´
µç×ÓÐÅÏ¢µ÷¼Á½»²æÑ§¿ÆÓÐÍÆ¼öÂð
ÒѾÓÐ9È˻ظ´
²ÄÁϹ¤³Ìר˶Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
allain
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 2
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3279.6
- É¢½ð: 2
- ɳ·¢: 1
- Ìû×Ó: 1799
- ÔÚÏß: 135.8Сʱ
- ³æºÅ: 893736
- ×¢²á: 2009-11-04
- ÐÔ±ð: GG
- רҵ: ÎÞ»ú²ÄÁÏ»¯Ñ§
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
wangshixiaowsx(½ð±Ò+6): 1-24 22:17
wangshixiaowsx(½ð±Ò+6): 1-24 22:17
|
A general overview of study of open-loop nucleoside antiviral drugs Abstract: Open-loop nucleoside antiviral drugs have low toxicity, low tolerance and wide-spectrum of anti-DNA virus activity, and furthermore the prodrugs have improved the oral bioavailability. In this paper, the research process of several common kinds of open-loop nucleoside drugs and the prodrugs in recent years was generalized, and on this basis, the research direction of antiviral drugs was forcasted. |
2Â¥2010-01-24 21:44:10














»Ø¸´´ËÂ¥